Demographic variables and clinical profiles of patient (bvFTD, AD) and control groups (M±SD)
| bvFTD (n=14) | AD (n=14) | Controls (n=33) | H/χ2value | |
|---|---|---|---|---|
| Sex (M:F) | 10:4 | 5:9 | 12:21 | NS |
| Age | 62.7±8.9 | 64.9±8.1 | 67.5±8 | NS‡ |
| Education | 12.2±0.4 | 11.8±3.4 | 14.3±2.9 | NS‡ |
| Disease duration (months) | 57.8±37.7 | 53.5±26.3 | NA | NS |
| CBI | 40.8±18.2 | 16.7±8.8 | 5.4±5.0 | ***§,¶ |
| ACE-III (/100) | 68.2±9 | 70.7±9 | 96.4±2.7 | ***§ |
| Hayling test | 2.3±1.9 | 4.4±1.7 | 6.1±0.8 | ***§,¶ |
| Digit span (B) | 4.3±1.9 | 4.4±1.4 | 8.4±2.9 | **§ |
| TMT B | 141.8±73.9 | 177±92.6 | 74.1±27.7 | ***§ |
| FES total | 5.07±3.1 | 8.9±2 | 12.4±1.1 | ***§,¶ |
| Fluency | 1.5±1.7 | 3.6±1.2 | 4.6±0.7 | ***§,¶ |
| Inhibition | 1.3±1.4 | 2.7±1.3 | 4.3±0.7 | ***§,¶ |
| Working memory | 2.3±0.9 | 2.8±0.9 | 3.8±1.0 | ***§ |
Significant Tukey post hoc tests (p<0.05).
***p<0.001; **p<0.01; *p<0.05.
‡ANOVA F test.
§Controls versus patient groups (bvFTD, AD).
¶bvFTD versus AD.
ACE-III, Addenbrooke's Cognitive Examination-III; AD, Alzheimer's disease; bvFTD, behavioural-variant frontotemporal dementia; CBI, Cambridge Behavioural Inventory; Digit Span (B), Digit Span Backward; FES Total, FRONTIER Executive Screen Total score; Hayling Test, Hayling Sentence Completion Test; NA, not applicable; NS, not significant ;TMT B, Trail Making Test Part B.